

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL)  
FOR THE QUARTER ENDED 30th June, 2014**

Part - I		(Rs. in millions)			
S. No.	PARTICULARS	Quarter Ended on		Year Ended	
		30/06/2014	31/03/2014	30/06/2013	31/03/2014
		Unaudited	Audited	Unaudited	Audited
<b>1</b>	<b>Net Sales/ Income from operations</b>				
	Gross Sales	1210.55	1375.11	1268.79	5195.44
	Less : Excise Duty	2.42	2.17	2.34	8.54
	(a) Net Sales	1208.13	1372.94	1266.45	5186.9
	(b) Other Operating Income	6.66	50.49	5.63	73.65
	<b>Total Income from Operation ( Net )</b>	<b>1,214.79</b>	<b>1,423.43</b>	<b>1,272.08</b>	<b>5,260.55</b>
<b>2</b>	<b>Expenses</b>				
	(a) Consumption of raw materials	629.42	853.78	752.50	3,012.81
	(b) (Increase)/ Decrease in stock in trade	49.12	(35.4)	(2.80)	(23.22)
	(c) Employee benefits expense	63.42	76.87	59.17	255.65
	(d) Depreciation & amortization expense	111.30	96.70	95.35	386.09
	(e) Other expenses	176.45	194.01	147.14	683.03
	<b>Total expense</b>	<b>1,034.16</b>	<b>1,185.96</b>	<b>1,051.36</b>	<b>4,314.36</b>
<b>3</b>	<b>Profit from operations before other income , finance costs and exceptional items ( 1-2)</b>	<b>180.63</b>	<b>237.47</b>	<b>220.72</b>	<b>946.19</b>
	<b>EBIDTA ( 3+2(d))</b>	<b>291.93</b>	<b>334.17</b>	<b>316.07</b>	<b>1,332.28</b>
<b>4</b>	Other income	1.00	1.92	8.18	4.06
<b>5</b>	<b>Profit before finance costs and exceptional items ( 3+4)</b>	<b>181.63</b>	<b>239.39</b>	<b>228.90</b>	<b>950.25</b>
<b>6</b>	Finance Costs	83.59	73.48	66.81	292.93
<b>7</b>	<b>Profit after finance costs but before exceptional items ( 5-6)</b>	<b>98.04</b>	<b>165.91</b>	<b>162.09</b>	<b>657.32</b>
<b>8</b>	Exceptional items	0.00	0.00	0.00	0.00
<b>9</b>	<b>Profit from ordinary activities before tax ( 7+8)</b>	<b>98.04</b>	<b>165.91</b>	<b>162.09</b>	<b>657.32</b>
<b>10</b>	Tax expense	0.00	24.82	08.97	47.82
<b>11</b>	<b>Profit from ordinary activities after tax (9-10 )</b>	<b>102.49</b>	<b>141.09</b>	<b>153.12</b>	<b>609.50</b>
<b>12</b>	Exceptional items ( net of tax expense	00.00	0.00	0.00	0.00
<b>13</b>	<b>Net profit for the period ( 11-12)</b>	<b>102.49</b>	<b>141.09</b>	<b>153.12</b>	<b>609.50</b>
<b>14</b>	<b>Paid up Equity Share Capital</b>	<b>114.42</b>	<b>114.42</b>	<b>114.42</b>	<b>114.42</b>
<b>15</b>	<b>Reserves excluding revaluation reserves</b>	<b>N. A.</b>	<b>N. A.</b>	<b>N. A.</b>	<b>4,520.26</b>
<b>16</b>	<b>E.P.S - Basic not annualized for the qtr</b>	<b>8.96</b>	<b>12.33</b>	<b>13.38</b>	<b>54.19</b>
	- Annualized	35.83	49.32	53.53	54.19

Part - II					
<b>1</b>	<b>Public Shareholding</b>				
	- Number of Shares	7154551	6437086	6437086	6437086
	- Percentage of Shareholding	62.53	56.26	56.26	56.26
<b>2</b>	<b>Promoters and promoter group shareholding</b>				
	<b>a) Pledged as collateral security to bank</b>				
	- Number of Shares	1937250	2080000	1930000	2080000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	45.18	41.56	38.56	41.56
	- Percentage of shares (as a % of the total share capital	16.93	18.18	16.87	18.18
	<b>b) Non-Encumbered</b>				
	- Number of Shares	2350187	2924902	3074902	2924902
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	54.82	58.44	61.44	58.44
	- Percentage of shares (as a % of the total share capital	20.54	25.56	26.87	25.56

Particulars	Quarter ended 30.06.2014
<b>(B) INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	1
Received during the quarter	NIL
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	NIL

For VENUS REMEDIES LIMITED  
  
 CHAIRMAN & MANAGING DIRECTOR

**Notes:**

1. The above financial Results were reviewed by the Audit Committee and taken on record at the Board Meeting on August 13, 2014.
2. During the Quarter:
  - a) Venus Remedies gets marketing nod from Venezuela for meropenem
  - b) Venus Remedies bags Market Authorization of Meropenem Injection from, TGA, Australia
  - c) Venus Remedies bags additional patent for Vancoplus from US
  - d) VMRC Drug VRP008 to Fight "MULTI-DRUG Resistant Bacteria" Received European Patent
3. Investor Complaints pending during the beginning of the quarter-1, Received during the quarter-NIL, Disposed of during the quarter-NIL, Remaining unresolved at the end of the quarter-NIL
4. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

**For and on behalf of Board of Directors  
For VENUS REMEDIES LIMITED**



**(Pawan Chaudhary)  
Chairman & Managing Director**

Date : 13.08.2014